Prognosis
White House Pulls the Plug on Proposed Drug-Rebate Overhaul
- Trump administration had sought to end rebates for drug plans
- Move sends shares of drug-plan giants CVS, UnitedHealth higher
This article is for subscribers only.
The White House abandoned a push to end rebates paid to middlemen who negotiate drug prices on behalf of health insurers, a move that could turn scrutiny back on how drugmakers themselves set prices.
President Donald Trump has made lowering prescription-drug costs a top priority of his administration, and ending rebates was seen as a vital part of that effort.